VivoSeq
Oncology

Clinical Stage I Gastric Cancer AJCC V8

9

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Clinical Stage I Gastric Cancer AJCC v8 is an early-stage landscape with 9 programs across 5 companies. The most active players are Teva, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Roche.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

2 programs

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2A

Avyxa

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Enrolling by invitation1 · 50%

Clinical Trials

Trial Activity

A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05836584·2 enrolled
Prophylactic Hyperthermic IntraperitOneal Chemotherapy (p-HIPEC) for pRevention of perItONeal Recurrence in Gastric Cancer: MC240402 (HORIZON) Trial
Enrolling by invitation·MMayo Clinic·Phase 2·NCT07139951·16 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)